Results 61 to 70 of about 14,463 (218)

Clinical Performance of a Liquid Preservation Medium for Cervicovaginal Samples in DNA‐HPV Testing and Liquid‐Based Cytology for Cervical Cancer Screening

Cytopathology, EarlyView.
The study evaluated the performance of a new liquid preservation medium for cervical samples in DNA‐HPV testing and liquid‐based cytology. The candidate medium demonstrated a 94.5% agreement rate in HPV testing, 92.9% sensitivity for detecting CIN2+ and good performance in liquid‐based cytology.
Larissa Dias Assunção, Michelle Garcia Discacciati, Andressa Germano da Silva, Adriana Yoshida, Diama Bhadra Vale, Julio Cesar Teixeira   +5 more
wiley   +1 more source

“It's like it's the old boys club”—the age‐related experiences of diverse older women living with HIV: A scoping review and consultative exercise

HIV Medicine, Volume 26, Issue 4, Page 546-568, April 2025.
Abstract Objectives HIV is often under‐recognized in older individuals, particularly women, despite a significant number of new cases being diagnosed in those aged >50 years. This review aimed to understand the age‐related experiences and challenges faced by women aged ≥50 years living with HIV through an intersectional perspective.
Kristina M. Kokorelias, Esther Su, Paige Brown, Stuart McKinlay, Ashley Flanagan, Sharon Walmsley, Alice Zhabokritsky, Katie Lee, Luxey Sirisegaram   +8 more
wiley   +1 more source

Prevalence of human papillomavirus (HPV) and HPV-16 genotyping by real-time PCR in patients with several cervical pathologies

Brazilian Journal of Infectious Diseases, 2010
Purpose: This study was planned to evaluate the prevalence of HPV (excepting type 16) and HPV 16 by real-time PCR in colposcopy patients and to interprete the results with age, age of first sexual intercourse (FSI), parity and Pap smear results. Methods:
Bedia Dinc, Seyyal Rota, Anil Onan, Gulendam Bozdayi, Cagatay Taskiran, Aydan Biri, Haldun Güner   +6 more
doaj  

Comprehensive management of vulvovaginal cancers

CA: A Cancer Journal for Clinicians, EarlyView.
Abstract Vulvar and vaginal cancers represent rare malignancies, with an incidence of 2.7 per 100,000 women for vulvar cancer, predominantly affecting women older than 60 years, although rising rates are observed in younger demographics. Approximately 90% of vulvar cancers are squamous cell carcinoma and frequently are associated with human ...
Angélica Nogueira‐Rodrigues, Maaike H. M. Oonk, Domenica Lorusso, Brian Slomovitz, Mario M. Leitão Jr, Glauco Baiocchi   +5 more
wiley   +1 more source

Analysis of colposcopy recall cases and influencing factors for women with positive cervical cancer screening in Ordos city

Zhongguo gonggong weisheng
ObjectiveTo investigate the situation and influencing factors of recall colposcopy attendance among women with positive cervical cancer screening results in Ordos city, in order to provide a reference for improving colposcopy recall compliance ...
Sumeng WANG, Le DANG, Yufei LI, Sensen TAN, Le ZHANG, Jiayi MA, Youlin QIAO, Fanghui ZHAO   +7 more
doaj   +1 more source

Assessment of Cervical Cancer Molecular-Based Screening Tools; HPV-DNA Detection versus E6/E7 mRNA Testing; First Report of a Prospective Cohort Study among Iranian Women

Iranian Journal of Public Health, 2020
Background: Human papillomavirus (HPV) has been found as the most considerable causes of cervical cancer. Recently, several molecular methods have been introduced to increase the accuracy of the screening programs and decrease the mortality rate.
Azam-Sadat MOUSAVI, Ali POURYASIN, Fariba YARANDI, Leila PIRZADEH, Abbas ALIPOUR, Shakiba KHODADAD, Mohammad POURYASIN   +6 more
doaj   +1 more source

Risk of high‐grade cervical lesions in the second round of primary human papillomavirus testing in CervicalScreen Norway: A population‐based cohort study

International Journal of Cancer, Volume 157, Issue 2, Page 251-259, 15 July 2025.
What's new? Many countries are transitioning from cytology to human papillomavirus (HPV) testing as the primary cervical cancer screening test. This comprehensive evaluation of the second HPV screening round in CervicalScreen Norway among women returning 4–6 years after a first negative HPV test showed that their risk of testing positive was lower in ...
Tone Bjørge, Nathalie C. Støer, Sara K. Hverven, Mari Nygård, Ameli Tropé, Birgit Engesæter   +5 more
wiley   +1 more source

DNA methylation signatures of cervical pre‐invasive and invasive disease: An epigenome‐wide association study

International Journal of Cancer, Volume 157, Issue 2, Page 305-316, 15 July 2025.
What's new? Cervical cancer screening programmes could benefit from an accurate triage test for human papillomavirus‐positive women based on self‐sampling. This epigenome‐wide association study examined a large number of cervical cancers and cervical intraepithelial neoplasias grade 3 (CIN3) compared to controls using the 850 k EPIC methylation array ...
Sarah J. Bowden, Barbara Bodinier, Maria Paraskevaidi, Ilkka Kalliala, Maria Nasioutziki, Laura Burney Ellis, Ruben Colindres Zuehlke, James M. Flanagan, Maria Kyrgiou, Marc Chadeau‐Hyam   +9 more
wiley   +1 more source

Ensembles of Radial Basis Function Networks for Spectroscopic Detection of Cervical Pre-Cancer [PDF]

IEEE Transactions on Biomedical Engineering, vol 45, no. 8, pp 953-962, 1998, 1999
The mortality related to cervical cancer can be substantially reduced through early detection and treatment. However, current detection techniques, such as Pap smear and colposcopy, fail to achieve a concurrently high sensitivity and specificity. In vivo fluorescence spectroscopy is a technique which quickly, non-invasively and quantitatively probes ...
arxiv  

Technical, legal and ethical framework of cancer audit in cervical screening – Summary of best practices for organised programmes delineated through an expert group consultation

International Journal of Cancer, Volume 157, Issue 1, Page 32-40, 1 July 2025.
What's new? There have been increasing litigations against cervical screening programmes centred around cancer audits. This manuscript provides a comprehensive framework for conducting cancer audits in cervical screening programmes, addressing legal and ethical challenges, and ensuring effective outcomes.
Arunah Chandran, Anne Mackie, Peter Sasieni, Marc Arbyn, Andre L. Carvalho, Clement Chauvet, Walter Prendiville, Elisabete Weiderpass, Partha Basu, on behalf of CervScreen Technical Working Group, Peter Saseini, Anne Mackie, Marc Arbyn, Silvina Arrossi, Christine Bergeron, Mame‐Yaa Bosomtwi, Julia Brotherton, Joakim Dillner, Mary Donnelly, Sarah Fitzgibbon, Gráinne Gleeson, David Keegan, Rachel Kitonyo Devotsu, Ondřej Májek, Caroline Mason Mohan, Kirsten McCaffery, Dearbhail McDonald, Raúl Murillo, Fiona Ness, Groesbeck Parham, Philippa Pearmain, Linda Rabeneck, David Ritchie, Vasco Rosa Dias, Robert Smith, Cherian Varghese, Noirin Russel   +36 more
wiley   +1 more source